Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-08-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiachroniclymphomarituximablymphocytic
  Phrases that lowered it: allergymgrespiratoryunable toindex
• Collaborators: 3 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Phase: 2 (raises risk) · Design
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: not given (lowers risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history
• Maximum age: 75 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants NCT01488253 · started 2012 · scored riskier than 55% of active trials terminated
• Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma NCT00928018 · started 2009 · scored riskier than 51% of active trials completed
• Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT NCT02728700 · started 2016 · scored riskier than 94% of active trials terminated
• Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT NCT01246206 · started 2010 · scored riskier than 72% of active trials completed
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression NCT02891603 · started 2017 · scored riskier than 92% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.